EntreMed Receives Orphan Drug Designation For ENMD-2076 In Leukemia

EntreMed, Inc., announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the Company’s lead oncology drug candidate, ENMD-2076, for the treatment of acute myeloid leukemia (AML). Source: General Cancer News Articles Provided by Cancer Compass

BioSante Announces Additional Positive Leukemia Vaccine Results And Second FDA Orphan Drug Designation
EntreMed Initiates Phase 2 Study For ENMD-2076 In Ovarian Cancer
BioSante Announces FDA Orphan Drug Designation For GVAX Pancreatic Cancer Vaccine
EntreMed Initiates Second Site In ENMD-2076 Phase 2 Ovarian Cancer Study
Scientists At Cleveland Clinic Target Acute Myeloid Leukemia
Summary Box: FDA sees little benefit with Avastin
BioSante Announces Positive Leukemia Vaccine Results
GSK's TYKERB Receives Accelerated Approval For First-Line Combination Treatment Of Metastatic Breast Cancer
Neoprobe Announces Successful Meeting On Lymphoseek Phase 3 Results
FDA Approves Zyclara Imiquimod Cream, 3.75% For The Treatment Of Actinic Keratoses
FDA Approves New Treatment For Advanced Prostate Cancer
Penn Researchers Find Genetic Link To Leukemias With An Unknown Origin
Jevtana Cabazitaxel Injection Approved By U.S. FDA After Priority Review
Possible Heart Risk In Men Taking Avodart For Prostate Cancer Prevention
Research Trial Evaluating CytRx's Bafetinib In Brain Tumor Model To Be Presented At The American Society Of Clinical Oncology ASCO Annual Meeting

Tags: Designation, Drug, ENMD2076, EntreMed, Leukemia, Orphan, Receives
Posted in Cancer on | There are currently No Comments

Cancer Cure Books

Sponsored Links

EntreMed Receives Orphan Drug Designation For ENMD-2076 In Leukemia

Related Posts:

Leave a Reply